TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04211545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480
Study: NCT01375114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng
Description: 400 mg by mouth twice daily from Day 1-29.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice daily for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Study: NCT04509700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + itacitinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + ruxolitinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + ibrutinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Study: NCT01735110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfemoral intervention (TFI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transradial intervention
Study: NCT02749487

Intervention type: OTHER
Intervention: Neutrophil Lymphocyte Ratio
Description: Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.

Intervention type: OTHER
Intervention: Neutrophil Lymphocyte Ratio
Description: Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
Study: NCT04363307

Intervention type: DEVICE
Intervention: AF Ablation
Description: Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT

Intervention type: DEVICE
Intervention: MRI
Description: Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
Study: NCT02620865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01011205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: IV infusion
Study: NCT02620865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02099591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Opioid Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Opioid Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Opioid Antagonist
Study: NCT01375114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Study: NCT01011205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV bolus
Study: NCT04329949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant, 100 mg and 25 mg
Description: Relacorilant is supplied as capsules for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT01375114

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Study: NCT02182037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single rising doses of BIBT 1011 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBT 1011 BS placebo
Study: NCT01115023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron cooking pot
Description: the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
Study: NCT04619342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSMs-TACE
Description: TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSMs-TACE
Description: TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of PVTT
Study: NCT02099591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Opioid Antagonist
Study: NCT03631329

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonographic measurement
Description: First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
Study: NCT04002323

Intervention type: DRUG
Intervention: Dolutegravir 50mg Tab
Description: The subjects starts their ART with this drugs, once a day

Intervention type: DRUG
Intervention: Lamivudine 300 mg
Description: The subjects starts their ART with this drugs, once a day
Study: NCT00784069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd Breeze)
Study: NCT02825953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surfactant
Description: the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surfactant
Description: the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surfactant
Description: the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
Study: NCT02825953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive intermittent positive-pressure ventilation
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
Study: NCT04373369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
Study: NCT00683553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP
Description: Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: I5NP
Description: Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV injection of saline
Study: NCT03825042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A mix of bioactive natural compounds
Description: A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive compound in oral tablets
Study: NCT03305211

Intervention type: OTHER
Group type: OTHER
Intervention: sample
Description: Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
Study: NCT03841877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endodontic treatment
Description: The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endodontic treatment
Description: The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
Study: NCT00821821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo
Study: NCT04211155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
Study: NCT00379483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT02764866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep testing
Description: Home sleep testing
Study: NCT00077181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT04211155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
Study: NCT03780322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring Pediatric
Description: Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical and occupational therapy
Description: Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions.
Study: NCT00077181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04044547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, extended-release microspheres
Description: Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Study: NCT02825953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive intermittent positive-pressure ventilation
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
Study: NCT04044547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, extended-release microspheres
Description: Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Study: NCT02825953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive intermittent positive-pressure ventilation
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff
Description: Fisher and Paykel, Auckland, New Zealand

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff
Description: Fisher and Paykel, Auckland, New Zealand

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff
Description: Fisher and Paykel, Auckland, New Zealand

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neonatal ventilator
Description: GE Healthcare, Madison, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neonatal ventilator
Description: GE Healthcare, Madison, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neonatal ventilator
Description: GE Healthcare, Madison, USA
Study: NCT01916369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX DP
Description: Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
Study: NCT00964678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: twice daily oral treatment in escalating dose
Study: NCT03033693

Intervention type: OTHER
Group type: OTHER
Intervention: Bispectral index will be targeted at 50
Description: The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.

Intervention type: OTHER
Group type: OTHER
Intervention: Bispectral index will be targeted at 35
Description: The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
Study: NCT03000114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Aponeurotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XIAFLEX